Malignant mixed Mullerian tumor

Search Trials
Temsirolimus in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Status:
Terminated
Last Changed:
Nov 9, 2016
First Changed:
Feb 3, 2010
Disease(s):
Recurrent Uterine Sarcoma
Intervention(s):
temsirolimus
Gemcitabine and Docetaxel in Treating Patients With Recurrent or Persistent Uterine Cancer
Status:
Completed
Last Changed:
Jan 8, 2019
First Changed:
Jun 14, 2005
Disease(s):
Recurrent Uterine Corpus Sarcoma
Intervention(s):
Gemcitabine HydrochlorideDocetaxel
Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Cancer
Status:
Completed
Last Changed:
Dec 4, 2017
First Changed:
Jan 12, 2004
Disease(s):
Recurrent Uterine Sarcoma
Intervention(s):
imatinib mesylatelaboratory biomarker analysis
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
Status:
Completed
Last Changed:
Apr 19, 2018
First Changed:
Jul 23, 2010
Disease(s):
Recurrent Uterine Corpus Sarcoma
Intervention(s):
IxabepiloneLaboratory Biomarker Analysis
Oxaliplatin and Gemcitabine Followed by Radiation Therapy in the Management of Mixed Mullerian Tumors of the Uterus
Status:
Completed
Last Changed:
Aug 24, 2018
First Changed:
May 21, 2007
Disease(s):
Mixed Mullerian Tumors of the Uterus
Intervention(s):
GemcitabineOxaliplatinRadiation

Connect. Empower. Inspire.